Hims & Hers Health (NYSE:HIMS) Price Target Raised to $39.00

Hims & Hers Health (NYSE:HIMS) had its price target lifted by Truist Financial from $24.00 to $39.00 in a report published on Wednesday,Benzinga reports. Truist Financial currently has a hold rating on the stock.

Several other research analysts have also recently commented on the stock. BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target for the company. Leerink Partners increased their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Citigroup increased their price objective on Hims & Hers Health from $25.00 to $27.00 and gave the company a “sell” rating in a report on Tuesday. Finally, Needham & Company LLC boosted their target price on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $37.23.

Hims & Hers Health Trading Up 9.3 %

Hims & Hers Health stock opened at $45.20 on Wednesday. The firm has a market capitalization of $9.87 billion, a P/E ratio of 102.72 and a beta of 1.35. The stock’s fifty day simple moving average is $36.57 and its 200-day simple moving average is $26.66. Hims & Hers Health has a twelve month low of $11.20 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Sell-side analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00. Following the transaction, the insider now directly owns 169,803 shares in the company, valued at approximately $4,712,033.25. The trade was a 61.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Michael Chi sold 7,259 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $24.07, for a total transaction of $174,724.13. Following the sale, the insider now owns 193,601 shares of the company’s stock, valued at $4,659,976.07. This trade represents a 3.61 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,097,578 shares of company stock worth $38,080,320 in the last 90 days. 17.71% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of HIMS. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health during the fourth quarter worth $28,000. Raleigh Capital Management Inc. raised its position in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the last quarter. Blume Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 600 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter worth about $38,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.